Supplementary materials: Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

These are peer-reviewed supplementary materials for the article 'Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer' published in the Journal of Comparative Effectiveness Research.Table S1: Eligibility criteria for screeningTable S2: Search strategy for EmbaseTable S3: Search strategy for MEDLINETable S4: Search strategy for Cochrane Register of Controlled TrialsTable S5: Summary of absolute standardized difference and effective sample size when matched to the basket trial platinum-sensitive subgroup (n = 60)Table S6: Estimated odds ratios and hazard ratios for overall survival and overall response rate across sensitivity analysesTable S7: Estimated odds ratios from the fixed-effect network meta-analysis of hematological adverse eventsFigure S1: Network of trials included in the feasibility assessment, with visualization of platinum sensitivity statusFigure S2: Evidence networks for overall response rate, overall survival, grade 3/4 anemia, grade 3/4 thrombocytopenia, and grade 3/4 neutropenia for (A) sensitivity analysis #1 and (B) sensitivity analysis #2Figure S3: Results from network meta-analysis of progression-free survival/time to progression. Aim: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. Methods: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. Results: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). Conclusion: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.